Please assess the completion status of the following clinical trial:

Trial Title: The Effect of Nebivolol on Endothelial Dysfunction in African Americans With Hypertension

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Male or post-menopausal females aged 18-80 years.~* Subjects self-identified as black or African-American.~* Diagnosis of hypertension.~* Patients on current anti-hypertensive therapy that does not include beta blockade should have BP \>135/85.~* Patients on anti-hypertensive therapy including beta blockers will have their beta blockers discontinued gradually over 2 weeks before enrolment.~* Concomitant therapy: Patients will be allowed to be on concomitant therapy with aspirin, statins, thiazide diuretics, calcium antagonists (for treatment of hypertension), clonidine, or vasodilators. Patients will be on stable medical therapy for at least 2 months before recruitment. Patients with previous treatment with beta adrenergic blockers (metoprolol, propranolol, atenolol, and labetalol) will also be eligible to participate, but will be randomized to the study beta blocker.~Exclusion Criteria:~* Initiation or change in dose of statin or other anti-hypertensive therapy within 2 months before the study~* Inability to return to Emory for follow-up testing~* Age \< 21 or \>80 years~* Premenopausal females with potential for pregnancy~* Acute infection in previous 2 weeks~* On angiotensin antagonists (ACE inhibitors or ARBs)~* History of substance abuse~* Current neoplasm~* Chronic renal failure \[creatinine \> 2.5 mg/dL\] or liver failure (liver enzymes \>2X normal)~* Acute coronary syndrome, Class IV heart failure, CVA, coronary intervention within 2 months~* Known aortic stenosis, hypertrophic cardiomyopathy.~* Inability to give informed consent

- Gender: ALL
- Minimum Age: 21 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Nebivolol followed by Metoprolol XL (Type: ACTIVE_COMPARATOR): Subjects are randomized to Nebivolol 5mg and titrate to Nebivolol 10mg two weeks after drug initiation. Ten weeks after titration subjects will cross over to Metoprolol XL 50mg and titrate to Metoprolol XL 100mg two weeks after cross over.
- Metoprolol XL followed by Nebivolol (Type: ACTIVE_COMPARATOR): Subjects are randomized to Metoprolol XL 50mg and titrate to Metoprolol XL 100mg two weeks after drug initiation. Ten weeks after titration subjects will cross over to Nebivolol 5mg and titrate to Nebivolol 10mg two weeks after cross over.

Based on this trial design, predict the completion outcome and termination type (if applicable).